-
UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012
Monday, May 21, 2012
ATLANTA - UCB, Inc., a leading biopharmaceutical company dedicated to the research and development of treatments for severe central nervous system and immunological disordersis marking Digestive Disease Week (DDW) 2012 in San Diego by reinforcing its commitment to improving the lives of patients w
-
Pfizer Lung Drug Stops Deadly Child Cancers in Study
Monday, May 21, 2012
Pfizer Inc.’s Xalkori, a drug that targets lung cancer caused by a gene defect, wiped out all signs of malignancy in some children with different tumor types, in a study that proves aiming treatment at genes rather than disease sites may be more effectiveThe findings, being released today in adv
-
Telik Announces the Publication of Two Reports in the Journal of Hematology & Oncology
Monday, May 21, 2012
PALO ALTO, Calif. - Telik, Inc. announced two publications in the Journal of Hematology & OncologyThe first is "Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)," Raz
-
Analysis of Rilotumumab Data Identifies a Potential Predictive Biomarker for Patients With Gastric or Gastroesophageal Cancer
Monday, May 21, 2012
THOUSAND OAKS, Calif. - Amgen announced results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumabThis analysis, conducted on a previously reported Phase 2 study of rilotumumab in patients with locally advanced or metastatic gastric
-
Amgen's BiTE Antibody Blinatumomab Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Monday, May 21, 2012
THOUSAND OAKS, Calif. - Amgen announced updated results from a Phase 2 study that showed treatment with blinatumomab helped achieve a high-rate of complete response in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia treated in the studyBlinatumomab
-
Intellect Neurosciences Expands Its Immunotherapy Pipeline With New Technology Platforms Targeting Pathogenic Protein Aggregates Focused on Huntington's and Parkinson's Diseases
Monday, May 21, 2012
NEW YORK - Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseasesannounced it has filed three new patent applications with the United States Patent
-
MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in Vitro Models
Monday, May 21, 2012
WOONSOCKET, R.I. - MultiCell Technologies, Inc. is pleased to announce representatives from the Company will present preclinical research findings for MCT-465 and MCT-485 at CIMT 2012, Europe's largest meeting dedicated to cancer immunotherapy research and developmentCIMT 2012 will be held in May
-
Top Physicians and Scientists Meet for 2nd International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
Monday, May 21, 2012
LOS ANGELES - At the 2nd Annual Symposium for Lung-Sparing Therapies for Malignant Pleural Mesothelioma held this weekend at the Sheraton Delfina in Santa Monica, CAinternational experts again re-affirmed the general consensus that radical operations which remove a patient's lung, such as extraple
-
Children With Cancer Have Complete Responses in a Children's Oncology Group Phase 1 Trial
Monday, May 21, 2012
PHILADELPHIA - A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastomaA phase 1 clinical trial of the drug crizotinib achie
-
Gene Therapy for Brain Disease
Monday, May 21, 2012
An inherited disorder known as aromatic L-amino acid decarboxylase deficiency, or AADC, leaves patients unable to produce the neurotransmitter dopamine, leaving them nearly paralyzed until they die in early childhoodBut a new gene therapy, which involves the delivery of the missing L-amino acid de